Latest filing published 10 Oct 2017 for Rhythm Pharmaceuticals, INC..
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of Ipsen, S.A. across 2 companies, led by Tercica Inc and Rhythm Pharmaceuticals, Inc. The record holds 10 filings, for trades running from 13 October 2006 to 10 October 2017.
The open-market record is one-sided, with 4 purchases worth €66.6M and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2017 to date brings 1 purchase and no sales.
A typical purchase (the median) is worth €2.2M.
The newest entry dates from 10 October 2017: an open-market purchase of €288k, in Rhythm Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations